A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to <6 years with severe atopic dermatitis PIP number: P/069/2017

Trial Profile

A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to <6 years with severe atopic dermatitis PIP number: P/069/2017

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 May 2018

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms Liberty AD PRESCHOOL
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 01 May 2018 Planned End Date changed from 29 Mar 2022 to 15 Apr 2022.
    • 01 May 2018 Planned primary completion date changed from 6 Jan 2022 to 20 Jan 2022.
    • 08 Feb 2018 According to a Regeneron Pharmaceuticals media release, the trial was initiated in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top